Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Reading the posts makes me wonder why Lilly get bebtelovimab EUA approved prior to P3 trials/results.
A thought of mine: Could it be due to good P2 results (for it's own setting usage), combined with relatively large numbers of patients I.e being a large pharma have they been able to recruit and finance larger patient numbers in a P2 trial than Syn could afford to do? If so? Has this helped convince the approvers of its efficacy?
Sorry if that's not a potentially valid reason but I can't help wondering what is the reason., other than just simply the weight/influencers a large pharma will have.
We ain't got long to wait, tomorrow may be the big day.
Thanks again to ALL for the research information shared, always good to debate it nicely !!
Have a chilling Sunday, we may expend a lot of nervous (hopefully euphoric) energy tomorrow. If not "Que Sera Sera"
Regards to all.
Andybe4. The only cringeworthy post in this thread is yours.
I am acutely aware of why we need this drug to treat patients that are seriously ill. Arrogant of you to suggest otherwise.
I always try to be open minded and give people the benefit of the doubt, however your post is totally unjustified and undignified.
Fruits apologies for late reply regarding my previous post on this thread. As there seems to be some level of continued interest on this topic (There's a separate thread around this point now). I assume you will now know the somewhat tenuous link being made.......SNG in USA new company? Separate CEO required for that?
The guy lives relatively close to Delaware (Boston, just up the coast)
Stranger things could happen. Would they be able to announce appt of a new CEO before P3 results issue, would that be too obvious ?
JD76 post related:
https://www.takeda.com/who-we-are/company-information/executive-leadership/rajeev-venkayya/
He lives in Boston USA, quite close to Delaware!
Perhaps RM will retire on his fortune haha.